Ono Pharmaceutical Co. Ltd. has successfully completed its previously announced tender offer to acquire all outstanding shares of common stock of U.S. biopharmaceutical company Deciphera Pharmaceuticals Inc. for $25.60 per share (total amount of approximately $2.4 billion), through its wholly-owned subsidiary, Topaz Merger Sub Inc.
 
Following the completion of the tender offer, Merger Sub merged with and into Deciphera with Deciphera continuing as the surviving corporation and a wholly owned subsidiary of Ono.
 
“We are very pleased to welcome Deciphera into the family,” said Gyo Sagara, Chairman and CEO of Ono. “Through this acquisition, we will leverage Deciphera’s excellent research and development capabilities in the oncology field and its sales power in Europe and the United States, and work to further accelerate the expansion of our pipeline and global expansion, which are part of our growth strategies.”
 
“We are excited to enter a new phase as part of the family of Ono Pharmaceuticals,” said Steven L. Hoerter, President and CEO of Deciphera. “By fully leveraging the research and development capabilities and commercialization platforms of both companies, we look forward to significantly contributing to the growth of the Ono Group as a global specialty pharma company.”

Related News